TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01308086
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
Study: NCT01308086
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles
Study: NCT01308086
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
Study: NCT03958058
Drug: Anti-borrelial antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study: NCT00900666
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
Study: NCT03769064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
Study: NCT00541125
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00541125
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04307953
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo during 6 month RCT, AZD0530 thereafter
Study: NCT02476890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
Study: NCT01804842
Drug: Met DR
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin delayed-release tablets
Study: NCT03444506
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03444506
Drug: DYMISTA nasal spray
Normalized name: Dymista Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183610
Drug: [14C] BI 1356 as oral (p.o.) solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183610
Drug: [14C] BI 1356 solution for i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03285490
Drug: KX2-391 Ointment 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 1% (250 mg single-use packets); Dosage form: Ointment; Route of administration: Topical
Study: NCT03285490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Ointment; Route of administration: Topical
Study: NCT02728206
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT01633528
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg
Study: NCT00288691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02387450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with same presentation as the active drug
Study: NCT01272232
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study: NCT02218645
Drug: WE 941 OD tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04353128
Drug: Melatonin 2mg
Normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
Study: NCT04353128
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically looking placebo tablets P.O. before bedtime for 12 weeks
Study: NCT00040443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00980135
Drug: Hydrocortison cream
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Application over 29 days
Study: NCT01137032
Drug: Pandel Cream 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
Study: NCT01594229
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
Study: NCT01979393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02041481
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02041481
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02806869
Drug: Single dose of ibuprofen (800 mg tablet)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02652936
Drug: AF-130
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
Study: NCT02652936
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF-130 matching placebo capsule
Study: NCT03745001
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid administration daily
Study: NCT00591162
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
Study: NCT01789255
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002963
Drug: aminolevulinic acid hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01834638
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule(s)
Study: NCT01687296
Drug: placebo inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml 0.9% saline nebulized twice daily
Study: NCT01687296
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo soluble tablet, oral ,once daily
Study: NCT01969006
Drug: Marcaine ½%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02624440
Drug: Standard myeloma treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
Study: NCT02624440
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P.o. clarithromycin 250 mg twice daily
Study: NCT03745404
Drug: Placebo Plaster
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02155504
Drug: ASP3700
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02624440
Drug: Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation without prophylactic antibiotic
Study: NCT02155504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02314286
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
Study: NCT02314286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929512
Drug: HCP1201 750/20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Study: NCT01929512
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Study: NCT03275740
Drug: PF-06755347 intravenous healthy participant
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.
Study: NCT00736606
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One single dose of 40mg
Study: NCT03275740
Drug: Placebo intravenous healthy participant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03275740
Drug: PF-06755347 subcutaneous healthy participant
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
Study: NCT03275740
Drug: Placebo subcutaneous healthy participant
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT03275740
Drug: PF-06755347 subcutaneous ITP
Approvals — FDA: no, EMA: no, PMDA: no
Description: single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
Study: NCT01410513
Drug: SAR245409
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT00736606
Drug: AZD9056 + simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
Study: NCT02498769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00509470
Drug: telmisartan plus hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
Study: NCT04648813
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered daily, 2 inhalations per dose for a total of 8 doses
Study: NCT01129414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Study: NCT00238979
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01964417
Drug: Colonoscopy after bowel cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02519699
Drug: norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increase in mean arterial pressure using norepinephrine
Study: NCT03744767
Drug: Spironolactone 50 MG
Normalized name: spironolactone 50 MG
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
Study: NCT02486016
Drug: Duragesic reference fentanyl TDS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 µg/hour
Study: NCT02486016
Drug: Apotex generic fentanyl TDS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 µg/hour
Study: NCT02486016
Drug: Mylan generic fentanyl TDS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 µg/hour
Study: NCT03667157
Drug: every week IVMP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
Study: NCT02509923
Drug: Z-215 10mg
Normalized name: zinc pyrithione 10 MG/ML [Theraplex Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-215 10mg, capsules
Study: NCT02509923
Drug: Z-215 20mg
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Z-215 20mg, capsules
Study: NCT01292187
Drug: Oral calcitonin at dinnertime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral calcitonin at dinnertime.
Study: NCT01292187
Drug: Oral placebo at dinnertime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo at dinnertime.
Study: NCT01292187
Drug: Oral calcitonin at bedtime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral calcitonin at bedtime
Study: NCT01292187
Drug: Oral placebo at bedtime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo at bedtime
Study: NCT03031444
Drug: FOLFIRI/FOLFOX/CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
Study: NCT00243750
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00667745
Drug: Optimized Treatment (OPT)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
Study: NCT01884636
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT04013646
Drug: Umbilical cord blood infusion
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Study: NCT04013646
Drug: Placebo umbilical cord blood infusion
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
Study: NCT01063517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg BID oral tablet to match olaparib tablet
Study: NCT01682200
Drug: ProOxy
Normalized name: 2-propoxy-1-propanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
Study: NCT03547804
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
Study: NCT00255437
Drug: ferumoxytol or oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03119636
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa is used depending on the patient's condition
Study: NCT01366898
Drug: Dexamethasona, Idarubicine, ARA-C, Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01725490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
Study: NCT02550067
Drug: LNG
Normalized name: Jobst Knee High White LNGT Beige Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
Study: NCT03742973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00166829
Drug: sirolimus, tacrolimus, mycophenolate mofetil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03221569
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
Study: NCT01861626
Drug: V0057 - A mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration
Study: NCT01155336
Drug: Lovaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza® is prescription grade EPA+DHA fish oil supplement.
Study: NCT00207311
Drug: Xenical, Pegasys, Copegus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
Study: NCT03221569
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine.
Study: NCT02360826
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02360826
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03221569
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml intravenous push as placebo for double-blinding purposes
Study: NCT03619616
Drug: ZSP1603 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Study: NCT05084586
Drug: Intravesical Solution
Normalized name: Rimso-50 Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 150 ml saline was continuously instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
Study: NCT05084586
Drug: Intravesical Solution
Normalized name: Rimso-50 Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the Transurethral Resection of Bladder Tumor(TURBT) surgery, 50 mg Epirubicin solution in 50 ml saline was instiled into the bladder for 2 hours. A drainage catheter was closed in order to fill the bladder with epirubicin solution.
Study: NCT01695135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 tablets) taken orally once daily
Study: NCT03619616
Drug: ZSP1603 12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1603 capsule administered orally once daily in the fasting state.
Study: NCT01488526
Drug: TDF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
Study: NCT01434173
Drug: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
Study: NCT02031510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transversus abdominis plane block with saline 0.9%
Study: NCT00490269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03619616
Drug: ZSP1603 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Study: NCT03619616
Drug: Placebo 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
Study: NCT00269516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01101152
Drug: Desvenlafaxine succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day
Study: NCT00726999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no